NCT06969027View on ClinicalTrials.gov

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

JS207

JS207 (10 mg/kg or 15 mg/kg, IV, d1)

DRUG

Pemetrexed injection

Pemetrexed (500 mg/m2 IV, D1)

DRUG

Platinum

Platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1)

DRUG

Paclitaxel

Paclitaxel (175 mg/m2 IV, D1)

Trial Locations (1)

250117

RECRUITING

Shandong First Medical University Affiliated Neoplasm Hospital, Jinan

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER